Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen

American Journal of Physical Medicine and Rehabilitation

Volumn 92, Issue 8, 2013, Pages 728-733

  Pratini, Napala R ^a   Sweeters, Nancy ^a   Vichinsky, Elliott ^a   Neufeld, Jacob A ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Baclofen; Deferiprone; Neurodegeneration with brain iron accumulation; Pantothenate kinase associated neurodegeneration

Indexed keywords

BACLOFEN; CENTRAL MUSCLE RELAXANT; DEFERIPRONE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ARTICLE; CASE REPORT; DRUG COMBINATION; HUMAN; INTRASPINAL DRUG ADMINISTRATION; MALE; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; BACLOFEN; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, SPINAL; IRON CHELATING AGENTS; MALE; MUSCLE RELAXANTS, CENTRAL; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PYRIDONES;

EID: 84880924945     PISSN: 08949115     EISSN: 15377385     Source Type: Journal    
DOI: 10.1097/PHM.0b013e318282d209     Document Type: Article

References (19)

1. Kurian MA, McNeill A, Lin JP, et al: Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol 2011;53: 394-404
2. Hayflick SJ, Hogarth P: As iron goes, so goes disease? Haematologica 2011;96:1571-2
3. Gregory A, Polster BJ, Hayflick SJ: Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009;46:73-80
4. Gregory A, Hayflick SJ: Pantothenate kinase-Associated neurodegeneration. 2002 Aug 13 [updated 2010 Mar 23], in: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds): GeneReviewsi[Internet]. Seattle, WA, University of Washington, 1993
5. Woon K, Tsegaye M, Vloeberghs MH: The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg 2007;21:355-8
6. Narayan RK, Loubser PG, Jankovic J, et al: Intrathecal baclofen for intractable axial dystonia. Neurology 1991;41:1141-2
7. Ford B, Greene P, Louis ED, et al: Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996;53:1241-6
8. Albright AL, Barry M, Fasick P, et al: Continuous intrathecal baclofen infusion for symptomatic generalized dystonia [clinical studies]. Neurosurgery 1996;38:934-9
9. Albright AL, Ferson SS: Intraventricular baclofen for dystonia: Techniques and outcomes. Clinical article. J Neurosurg Pediatr 2009;3:11-4
10. Fredenburg AM, Sethi RK, Allen DD, et al: The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-10ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996;108:191-9
11. Habgood MD, Liu ZD, Dehkordi LS, et al: Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem Pharmacol 1999;57:1305-10
12. Kakhlon O, Breuer B, Munnich A, et al: Neurological disorders associated with iron misdistribution: the therapeutic potential of siderophores, in: Gadoth N, Goebel H, Oxidative Stress and Free Radical Damage in Neurology. New York, Humana, 2011, pp. 169-90
13. Waldmeier PC, Buchle AM, Steulet AF: Inhibition of catechol-O- methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol 1993;45:2417-24
14. Forni GL, Balocco M, Cremonesi L, et al: Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008;23:904-7
15. Abbruzzese G, Cossu G, Balocco M, et al: A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011;96:1708-11
16. Zorzi G, Zibordi F, Chiapparini L, et al: Iron-related MRI images in patients with pantothenate kinaseassociated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Mov Disord 2011;26:1755-9
17. Coubes P, Cif L, El Fertit H, et al: Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: Long-Term results. J Neurosurg 2004;101:189-94
18. Cif L, Valente EM, Hemm S, et al: Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004;19:724-7
19. Albright AL, Barry MJ, Shafton DH, et al: Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652-7